• |
2023 Start of Production (SOP) remains on track – the Company believes that full production launches for Innoviz’s BMW and Shuttle programs remain on track, with volumes expected to increase in
the second half of 2023.
|
• |
Volkswagen program is on track and exploring additional business opportunities – the Company’s Volkswagen CARIAD program remains on track for a mid-decade launch and is progressing well.
Furthermore, the Company is in advanced discussions that are exploring additional business opportunities with the Volkswagen Group.
|
• |
Continued growth and expansion in its customer pipeline – during the fourth quarter the Company saw further growth in its customer RFI/RFQ pipeline, including the addition of a multi-million
unit LiDAR RFI. The Company’s pipeline for potential LiDAR orders is now over 20 million LIDAR units, and the Company believes the 10-15 programs currently in the pipeline represent an estimated opportunity to quote non-recurring
engineering (NRE) bookings in the range of $150 to $250 million.
|
• |
Innoviz added Steven Schondorf as a senior strategic advisor – Schondorf is an experienced leader in automotive driver assistance systems, active safety, passive safety and safety electronics.
He spent 30 years at Ford Motor Company, most recently as the Chief Engineer of ADAS Systems, Hardware and Features, where he was responsible for evaluating early-stage technologies and built the company’s system architecture and overall
product strategy, including features like Ford’s BlueCruise hands-free driving system. Innoviz believes Schondorf’s expertise will help accelerate the Company’s evolution towards becoming a leading Tier 1 direct supplier of LiDAR to
automotive OEMs around the world.
|
• |
Innoviz 360 debuted at CES – in only one year, Innoviz progressed from announcing plans for a new 360-degree LiDAR at CES in January 2022 to exhibiting a full sample unit with a live point cloud
at CES in January 2023. The Company has received significant customer interest relating to Innoviz 360 and it believes the market has a strong appetite for new solutions at Innoviz’s performance levels and price points.
|
• |
The Company won two new series production awards in 2022, ahead of its stated goal of adding at least one.
|
• |
The Company increased its forward-looking order book by +165% in 2022, ahead of its stated goal of +30%.
|
• |
The Company announced participation in 14 pre-production programs, ahead of its stated goal of 10.
|
• |
Win at least 2 new series production awards with new customers.
|
• |
Win at least 1-2 additional programs with existing customers.
|
• |
2023 revenues targeted in the range of $12-15 million and new NRE bookings targeted in the range of $20-40 million.
|
Investor Contact (US)
|
Investor Contact (Israel)
|
Rob Moffatt
|
Maya Lustig
|
VP, Corporate Development & IR
|
Director, Investor Relations
|
Innoviz Technologies
|
Innoviz Technologies
|
+1 (203) 665-8644
|
+972 54 677 8100
|
Investors@innoviz-tech.com
|
Investors@innoviz-tech.com
|
Year Ended
December 31,
|
||||||||
2022
|
2021
|
|||||||
(Unaudited)
|
(Audited)
|
|||||||
Revenues
|
$
|
6,026
|
$
|
5,466
|
||||
Cost of revenues
|
(14,790
|
)
|
(10,488
|
)
|
||||
Gross loss
|
(8,764
|
)
|
(5,022
|
)
|
||||
Operating expenses:
|
||||||||
Research and development
|
95,107
|
93,336
|
||||||
Sales and marketing
|
10,300
|
23,735
|
||||||
General and administrative
|
19,178
|
35,560
|
||||||
Total operating expenses
|
124,585
|
152,631
|
||||||
Operating loss
|
(133,349
|
)
|
(157,653
|
)
|
||||
Financial income, net
|
6,802
|
4,378
|
||||||
Loss before taxes on income
|
(126,547
|
)
|
(153,275
|
)
|
||||
Taxes on income
|
(325
|
)
|
(284
|
)
|
||||
Net loss
|
$
|
(126,872
|
)
|
$
|
(153,559
|
)
|
||
Basic and diluted net loss per ordinary share
|
$
|
(0.94
|
)
|
$
|
(1.54
|
)
|
||
Weighted average number of ordinary shares used in computing basic and diluted net loss per ordinary share
|
135,224,312
|
102,859,891
|
December 31,
|
December 31,
|
|||||||
2022
|
2021
|
|||||||
|
(Unaudited)
|
(Audited)
|
||||||
ASSETS
|
||||||||
CURRENT ASSETS:
|
||||||||
Cash and cash equivalents
|
$
|
55,718
|
$
|
23,640
|
||||
Short term restricted cash
|
236
|
901
|
||||||
Bank deposits
|
80,684
|
230,483
|
||||||
Marketable securities
|
41,681
|
11,607
|
||||||
Trade receivables, net
|
1,762
|
513
|
||||||
Inventory
|
4,236
|
4,256
|
||||||
Prepaid expenses and other current assets
|
3,236
|
3,029
|
||||||
Total current assets
|
187,553
|
274,429
|
||||||
LONG-TERM ASSETS:
|
||||||||
Marketable securities
|
7,840
|
38,289
|
||||||
Restricted deposits
|
2,543
|
-
|
||||||
Property and equipment, net
|
30,489
|
14,502
|
||||||
Operating lease right-of-use assets, net
|
26,927
|
-
|
||||||
Other long-term assets
|
81
|
-
|
||||||
Total long-term assets
|
67,880
|
52,791
|
||||||
Total assets
|
$
|
255,433
|
$
|
327,220
|
||||
LIABILITIES AND SHAREHOLDERS' EQUITY
|
||||||||
CURRENT LIABILITIES:
|
||||||||
Trade payables
|
$
|
8,367
|
$
|
5,764
|
||||
Advances from customers and deferred revenues
|
4,082
|
196
|
||||||
Employees and payroll accruals
|
8,693
|
8,997
|
||||||
Accrued expenses and other current liabilities
|
7,572
|
6,708
|
||||||
Operating lease liabilities
|
3,720
|
-
|
||||||
Total current liabilities
|
32,434
|
21,665
|
||||||
LONG-TERM LIABILITIES:
|
||||||||
Advances from customers and deferred revenues
|
61
|
4,517
|
||||||
Other liabilities
|
-
|
597
|
||||||
Operating lease liabilities
|
30,201
|
-
|
||||||
Warrants liability
|
720
|
1,639
|
||||||
Total long-term liabilities
|
30,982
|
6,753
|
||||||
SHAREHOLDERS' EQUITY:
|
||||||||
Ordinary Shares of no-par value
|
-
|
-
|
||||||
Additional paid-in capital
|
703,851
|
683,764
|
||||||
Accumulated deficit
|
(511,834
|
)
|
(384,962
|
)
|
||||
Total shareholders' equity
|
192,017
|
298,802
|
||||||
Total liabilities and shareholders' equity
|
$
|
255,433
|
$
|
327,220
|
Year Ended
December 31,
|
||||||||
2022
|
2021
|
|||||||
(Unaudited)
|
(Audited)
|
|||||||
Cash flows from operating activities:
|
||||||||
Net loss
|
$
|
(126,872
|
)
|
$
|
(153,559
|
)
|
||
Adjustments required to reconcile net loss to net cash used in operating activities:
|
||||||||
Depreciation and amortization
|
7,472
|
3,960
|
||||||
Remeasurement of warrants liability
|
(890
|
)
|
(1,216
|
)
|
||||
Issuance cost allocated to warrants liability
|
-
|
1,830
|
||||||
Increase in accrued interest on bank deposits
|
(705
|
)
|
(436
|
)
|
||||
Decrease in marketable securities
|
375
|
104
|
||||||
Share-based compensation
|
19,449
|
64,736
|
||||||
Realization of investment in non-marketable equity securities
|
-
|
(2,012
|
)
|
|||||
Capital gain
|
(44
|
)
|
-
|
|||||
Foreign exchange loss (gain), net
|
1,233
|
(577
|
)
|
|||||
Decrease (increase) in prepaid expenses and other assets
|
(377
|
)
|
620
|
|||||
Decrease (increase) in trade receivables, net
|
(1,249
|
)
|
1,993
|
|||||
Decrease (increase) in inventory
|
20
|
(2,092
|
)
|
|||||
Changes in operating lease assets and liabilities, net
|
6,530
|
-
|
||||||
Increase (decrease) in trade payables
|
1,082
|
(1,997
|
)
|
|||||
Increase in accrued expenses and other liabilities
|
607
|
3,076
|
||||||
Increase (decrease) in employees and payroll accruals
|
(304
|
)
|
3,469
|
|||||
Increase (decrease) in advances from customers and deferred revenues
|
262
|
(421
|
)
|
|||||
Net cash used in operating activities
|
(93,411
|
)
|
(82,522
|
)
|
||||
Cash flows from investing activities:
|
||||||||
Purchase of property and equipment
|
(22,567
|
)
|
(3,784
|
)
|
||||
Proceeds from sales of property and equipment
|
54
|
-
|
||||||
Investment in bank deposits
|
(79,500
|
)
|
(375,047
|
)
|
||||
Withdrawal of bank deposits
|
230,000
|
145,000
|
||||||
Decrease (increase) in restricted deposits
|
(2,633
|
)
|
56
|
|||||
Investment in marketable securities
|
-
|
(50,000
|
)
|
|||||
Proceeds from sale of non-marketable securities
|
-
|
2,178
|
||||||
Net cash provided by (used in) investing activities
|
125,354
|
(281,597
|
)
|
|||||
Cash flows from financing activities:
|
||||||||
Cash received from Transactions, net of issuance cost
|
-
|
121,357
|
||||||
Issuance of ordinary shares, net of issuance cost
|
-
|
217,507
|
||||||
Proceeds from exercise of options
|
609
|
952
|
||||||
Repayment of loans
|
-
|
(2,638
|
)
|
|||||
Net cash provided by financing activities
|
609
|
337,178
|
||||||
Effect of exchange rate changes on cash, cash equivalents and restricted cash
|
(1,139
|
)
|
716
|
|||||
Increase (decrease) in cash, cash equivalents and restricted cash
|
31,413
|
(26,225
|
)
|
|||||
Cash, cash equivalents and restricted cash at beginning of the period
|
24,541
|
50,766
|
||||||
Cash, cash equivalents and restricted cash at end of the period
|
$
|
55,954
|
$
|
24,541
|